Global Nuclear Medicine Diagnostics Market Anticipated To Grow To $13.76 Billion By 2030 At 11.7% CAGR
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Nuclear Medicine Diagnostics Market During The 2026–2030 Period?
The size of the nuclear medicine diagnostics market has experienced rapid expansion in recent years. It is projected to increase from $7.88 billion in 2025 to $8.84 billion in 2026, at a compound annual growth rate (CAGR) of 12.2%. The historical growth of this market can be attributed to several factors, including the increasing utilization of radioactive tracers in diagnostic procedures, the expansion of nuclear medicine units within hospitals, a rising demand for functional imaging techniques, the availability of technetium-based radiopharmaceuticals, and advancements in clinical research within the field of nuclear medicine.
The nuclear medicine diagnostics market size is projected to undergo rapid expansion in the coming years, with expectations to reach $13.77 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This expansion during the forecast period is primarily driven by escalating investments in theranostics, the increasing embrace of precision oncology diagnostics, the widening of PET imaging infrastructure, a growing emphasis on developing targeted radiopharmaceuticals, and enhanced regulatory support for nuclear diagnostics. Significant trends anticipated in this period include the rising adoption of PET-based diagnostic radiopharmaceuticals, an increasing demand for personalized nuclear diagnostics, the deepening integration of imaging and therapeutic applications, an expansion of oncology-focused nuclear medicine procedures, and a stronger focus on short-half-life radiotracers.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9415&type=smp
Which Major Factors Are Contributing To The Development Of The Nuclear Medicine Diagnostics Market?
The increasing incidence of cancer is anticipated to stimulate the expansion of the nuclear medicine diagnostics market moving forward. Cancer is defined as a cluster of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body, which can aggregate into a mass or tumor. The escalating prevalence of cancer stems from the world’s aging population, as the rate of cancer significantly increases with age, combined with advancements in healthcare extending life expectancy. Nuclear medicine diagnostics finds application in the detection, staging, and ongoing monitoring of various cancer types, employing radioactive substances that specialized cameras can detect to generate detailed images of the internal structures and operational functions of organs and tissues. For instance, in May 2025, according to the National Cancer Institute, a US-based intergovernmental organization, nearly 20 million people were diagnosed with cancer in 2022, and 9.7 million died from it; by 2050, these figures are projected to climb to 33 million new cases and 18.2 million deaths annually. Therefore, the escalating number of cancer cases is a significant factor driving the growth of the nuclear medicine diagnostics market.
How Are Different Segment Groups Identified Within The Nuclear Medicine Diagnostics Market?
The nuclear medicine diagnostics market covered in this report is segmented –
1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications
3) By End-User: Hospitals And Diagnostic Centers, Research Institutes
Subsegments:
1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals
2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals
Which Trends Are Supporting The Evolution Of The Nuclear Medicine Diagnostics Market?
Key companies within the nuclear medicine diagnostics market are concentrating on bringing forth sophisticated solutions, like advanced medical technologies, to secure a stronger competitive standing. Advanced medical technologies represent pioneering innovations in medicine aimed at improving patient health outcomes, elevating care standards, and fostering overall well-being. For example, in August 2023, Gleneagles Hospital, a healthcare service provider located in Malaysia, inaugurated its Nuclear Medicine Unit. This nuclear medicine unit functions as a specialized department within a hospital or medical facility, furnished with cutting-edge technology and staffed by highly proficient specialists. The purpose of this facility is to offer early detection, diagnosis, and treatment for various conditions utilizing nuclear medicine imaging methods.
Who Are The Major Companies Operating In The Nuclear Medicine Diagnostics Market?
Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacibasi-Monrol Nuclear Products Co.
Access The Complete Nuclear Medicine Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report
Which Geographic Region Represents The Largest Nuclear Medicine Diagnostics Market Share?
North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Nuclear Medicine Diagnostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report
Browse Through More Reports Similar to the Global Nuclear Medicine Diagnostics Market 2026, By The Business Research Company
Nuclear Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Nuclear Medicine Radioisotopes Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.